Europe - BIT:1VKTX - US92686J1060 - Common Stock
The current stock price of 1VKTX.MI is 21.43 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20.64 | 330.35B | ||
AMG.DE | AMGEN INC | 12.77 | 128.24B | ||
GIS.DE | GILEAD SCIENCES INC | 15.06 | 123.73B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 23.27 | 86.52B | ||
ARGX.BR | ARGENX SE | 87.2 | 39.44B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.45B | ||
IDP.DE | BIOGEN INC | 9.23 | 18.55B | ||
1MRNA.MI | MODERNA INC | N/A | 8.36B | ||
0QF.DE | MODERNA INC | N/A | 8.31B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B | ||
ABVX.PA | ABIVAX SA | N/A | 5.34B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.80B |
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 48 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA US
Employees: 48
Phone: 18587044660
The current stock price of 1VKTX.MI is 21.43 EUR. The price decreased by -6.99% in the last trading session.
The exchange symbol of VIKING THERAPEUTICS INC is 1VKTX and it is listed on the Euronext Milan exchange.
1VKTX.MI stock is listed on the Euronext Milan exchange.
VIKING THERAPEUTICS INC (1VKTX.MI) has a market capitalization of 2.41B EUR. This makes 1VKTX.MI a Mid Cap stock.
VIKING THERAPEUTICS INC (1VKTX.MI) currently has 48 employees.
VIKING THERAPEUTICS INC (1VKTX.MI) has a resistance level at 23.04. Check the full technical report for a detailed analysis of 1VKTX.MI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1VKTX.MI does not pay a dividend.
VIKING THERAPEUTICS INC (1VKTX.MI) will report earnings on 2025-10-21, after the market close.
VIKING THERAPEUTICS INC (1VKTX.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).
ChartMill assigns a technical rating of 2 / 10 to 1VKTX.MI.
ChartMill assigns a fundamental rating of 3 / 10 to 1VKTX.MI. While 1VKTX.MI has a great health rating, there are worries on its profitability.
Over the last trailing twelve months 1VKTX.MI reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS decreased by -62.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -20.72% | ||
ROE | -21.57% | ||
Debt/Equity | 0 |